Over 88% Of Wegovy Trial Participants Achieve Normal Liver Fat Levels, Novo Reports

Novo Nordisk A/S reported that over 88% of participants in the STEP UP trial achieved normal liver fat levels after treatment with Wegovy (semaglutide). The analysis involved 55 participants, revealing a decrease in mean liver fat from 8.8% to 3.1% by week 72. The trial included 1,919 adults, with 94% categorized as high risk for fatty liver. As of the latest update, Novo Nordisk's stock (NVO) is trading at $37.73, down 0.46%.